ARTICLE | Clinical News
Arzerra regulatory update
November 14, 2016 9:49 PM UTC
EMA’s CHMP recommended expanding the label of Arzerra ofatumumab from Novartis to include treatment of relapsed chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide....
BCIQ Target Profiles